Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.44 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.41 |
| ▸ | IKZF3 | Q9UKT9 | 6/20 | 0.40 |
| ▸ | IKZF1 | Q13422 | 5/20 | 0.40 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.40 |
| ▸ | TNF | P01375 | 5/20 | 0.40 |
| ▸ | IL1B | P01584 | 3/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30729349 | 0.86 | CRBN (0.45) | CRBNMAP1LC3BIKZF3IKZF1IKZF2 | |
| SCHEMBL30570135 | 0.86 | CRBN (0.45) | CRBNMAP1LC3BIKZF3IKZF1IKZF2 | |
| SCHEMBL26119732 | 0.85 | CRBN (0.50) | CRBNMAP1LC3BIKZF3IKZF1IKZF2 | |
| SCHEMBL26108552 | 0.84 | CRBN (0.43) | CRBNMAP1LC3BIKZF3IKZF1IKZF2 | |
| SCHEMBL30591590 | 0.84 | CRBN (0.43) | CRBNMAP1LC3BIKZF3IKZF1IKZF2 | |
| SCHEMBL26104721 | 0.82 | CRBN (0.48) | CRBNMAP1LC3BIKZF3IKZF1IKZF2 | |
| SCHEMBL30591663 | 0.81 | CRBN (0.44) | CRBNMAP1LC3BIKZF3IKZF1IKZF2 | |
| SCHEMBL26133304 | 0.81 | CRBN (0.44) | CRBNMAP1LC3BIKZF3IKZF1IKZF2 | |
| SCHEMBL31115998 | 0.81 | CRBN (0.48) | CRBNIKZF3IKZF1IKZF2TNF | |
| SCHEMBL31116486 | 0.81 | CRBN (0.41) | CRBNMAP1LC3BIKZF3IKZF1IKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028354-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | REGENT OF THE UNIV OF MICHIGAN (US) | 2026-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028354-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, ESRRB | CRBN 524/4885MAP1LC3B 4215/4885IKZF3 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.